CN107921130A - 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途 - Google Patents

能够结合b7‑h3和cd3的双特异性单价双抗体及其用途 Download PDF

Info

Publication number
CN107921130A
CN107921130A CN201680048182.7A CN201680048182A CN107921130A CN 107921130 A CN107921130 A CN 107921130A CN 201680048182 A CN201680048182 A CN 201680048182A CN 107921130 A CN107921130 A CN 107921130A
Authority
CN
China
Prior art keywords
cancer
ser
val
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680048182.7A
Other languages
English (en)
Chinese (zh)
Inventor
莱斯利·S·约翰逊
保罗·A·摩尔
埃兹奥·泊韦尼
黄菱
K·沙哈
拉尔夫·奥尔德森
格兰德·R·齐齐利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CN107921130A publication Critical patent/CN107921130A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680048182.7A 2015-08-17 2016-08-12 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途 Pending CN107921130A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562206051P 2015-08-17 2015-08-17
US62/206,051 2015-08-17
US201662280318P 2016-01-19 2016-01-19
US62/280,318 2016-01-19
PCT/US2016/046680 WO2017030926A1 (en) 2015-08-17 2016-08-12 Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
CN107921130A true CN107921130A (zh) 2018-04-17

Family

ID=58051498

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680048182.7A Pending CN107921130A (zh) 2015-08-17 2016-08-12 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途

Country Status (21)

Country Link
US (1) US20190002563A1 (https=)
EP (1) EP3337507A4 (https=)
JP (1) JP2018523686A (https=)
KR (1) KR20180038045A (https=)
CN (1) CN107921130A (https=)
AU (1) AU2016307955A1 (https=)
CA (1) CA2995709A1 (https=)
CL (1) CL2018000422A1 (https=)
CO (1) CO2018001485A2 (https=)
CR (1) CR20180105A (https=)
EA (1) EA201890443A1 (https=)
EC (1) ECSP18011248A (https=)
HK (1) HK1249423A1 (https=)
IL (1) IL257562A (https=)
MA (1) MA42665A (https=)
MX (1) MX2018001954A (https=)
PE (1) PE20181066A1 (https=)
PH (1) PH12018500363A1 (https=)
TW (1) TW201718652A (https=)
WO (1) WO2017030926A1 (https=)
ZA (1) ZA201800955B (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
WO2020114479A1 (zh) * 2018-12-07 2020-06-11 江苏恒瑞医药股份有限公司 多特异性蛋白分子
CN111454357A (zh) * 2019-08-14 2020-07-28 上海岺樾生物医药科技有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN112513092A (zh) * 2018-06-09 2021-03-16 勃林格殷格翰国际有限公司 Dll3-cd3双特异性抗体
CN114096563A (zh) * 2019-07-09 2022-02-25 Y生物股份有限公司 与b7-h3特异性结合的抗体及其用途
CN116323668A (zh) * 2020-07-17 2023-06-23 辉瑞公司 治疗性抗体及其用途
CN117903311A (zh) * 2024-03-20 2024-04-19 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3152235B1 (en) * 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EA201790719A1 (ru) * 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
AU2018250641B2 (en) 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
IL302613B2 (en) * 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109939232A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939230A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109971711A (zh) * 2017-12-27 2019-07-05 张曼 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
SG11202007572VA (en) * 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
BR112020020604A2 (pt) 2018-04-11 2021-01-12 Inhibrx, Inc. Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115082A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
MY207205A (en) 2018-12-07 2025-02-06 Shanghai hengrui pharmaceutical co ltd Cd3 antibody and pharmaceutical use thereof
EP3822288A1 (en) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
BR112022012437A2 (pt) * 2019-12-23 2022-09-20 Macrogenics Inc Método de tratamento de um câncer compreendendo a administração de uma molécula biespecífica pd-1 x lag-3 a um indivíduo em necessidade deste e método de tratamento de um câncer em um indivíduo
CN115380047A (zh) 2020-01-29 2022-11-22 印希比股份有限公司 Cd28单结构域抗体及其多价和多特异性构建体
EP4032910A1 (en) * 2021-01-22 2022-07-27 ETH Zurich Bispecific binding agent that binds to cd3 and a fluorophore
WO2022232392A2 (en) * 2021-04-28 2022-11-03 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
WO2025245264A1 (en) * 2024-05-21 2025-11-27 Briapro Therapeutics Corp. Anti-b7-h3 antibodies and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
CN102892426A (zh) * 2010-03-04 2013-01-23 宏观基因有限公司 与b7-h3反应性的抗体、其免疫学活性片段及其用途
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
CN108136010A (zh) * 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892426A (zh) * 2010-03-04 2013-01-23 宏观基因有限公司 与b7-h3反应性的抗体、其免疫学活性片段及其用途
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112513092A (zh) * 2018-06-09 2021-03-16 勃林格殷格翰国际有限公司 Dll3-cd3双特异性抗体
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
WO2020114479A1 (zh) * 2018-12-07 2020-06-11 江苏恒瑞医药股份有限公司 多特异性蛋白分子
CN112969476A (zh) * 2018-12-07 2021-06-15 江苏恒瑞医药股份有限公司 多特异性蛋白分子
CN112969476B (zh) * 2018-12-07 2024-06-14 江苏恒瑞医药股份有限公司 多特异性蛋白分子
CN114096563A (zh) * 2019-07-09 2022-02-25 Y生物股份有限公司 与b7-h3特异性结合的抗体及其用途
CN114096563B (zh) * 2019-07-09 2025-04-18 Y生物股份有限公司 与b7-h3特异性结合的抗体及其用途
CN111454357A (zh) * 2019-08-14 2020-07-28 上海岺樾生物医药科技有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
CN116323668A (zh) * 2020-07-17 2023-06-23 辉瑞公司 治疗性抗体及其用途
CN117903311A (zh) * 2024-03-20 2024-04-19 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof

Also Published As

Publication number Publication date
IL257562A (en) 2018-04-30
US20190002563A1 (en) 2019-01-03
AU2016307955A1 (en) 2018-03-08
CO2018001485A2 (es) 2018-07-10
CR20180105A (es) 2018-06-12
ECSP18011248A (es) 2018-04-30
WO2017030926A1 (en) 2017-02-23
EA201890443A1 (ru) 2018-09-28
EP3337507A4 (en) 2019-04-24
TW201718652A (zh) 2017-06-01
PE20181066A1 (es) 2018-07-04
CA2995709A1 (en) 2017-02-23
EP3337507A1 (en) 2018-06-27
MA42665A (fr) 2018-06-27
PH12018500363A1 (en) 2018-09-10
JP2018523686A (ja) 2018-08-23
KR20180038045A (ko) 2018-04-13
HK1249423A1 (zh) 2018-11-02
ZA201800955B (en) 2018-11-28
CL2018000422A1 (es) 2018-08-10
MX2018001954A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
CN107921130A (zh) 能够结合b7‑h3和cd3的双特异性单价双抗体及其用途
TWI788327B (zh) 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
CN112898432B (zh) 能结合CD32B和CD79b的双特异性单价Fc双抗体及其用途
TWI706960B (zh) 能夠結合cd19和cd3的雙特異性雙抗體及其用途
US20240117049A1 (en) Bispecific antigen binding molecules targeting ox40 and fap
TWI691509B (zh) Ｐｄ-１結合分子和其使用方法
TWI718098B (zh) 三特異性結合分子及其使用方法
KR102269584B1 (ko) Gpa33 및 cd3에 결합할 수 있는 이중특이성 1가 디아바디 및 그것의 용도
EP3161004B1 (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
CN109310762A (zh) 联合疗法
CN107614013A (zh) 结合lag‑3的分子和其使用方法
TW201627322A (zh) 抗-ｄｒ５抗體和包括其ｄｒ５-結合結構域的分子
JP2022120061A (ja) 炎症性疾患及び障害の治療におけるｃｄ３２ｂ×ｃｄ７９ｂ結合分子
TWI814758B (zh) 雙特異性ｃｄ１６-結合分子及其在疾病治療中的用途
RU2805648C2 (ru) Биспецифические связывающие молекулы, способные связывать cd137 и опухолевые антигены, и варианты их применения
HK40051187A (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
HK40051187B (zh) 能结合cd32b和cd79b的双特异性单价fc双抗体及其用途
HK1236976B (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417